KRAS-Mutant Models: Spotlight on SNU Cell Line Diversity

The KRAS gene is one of the most frequently mutated oncogenes in human cancers, particularly in pancreatic, colorectal, and lung adenocarcinomas. At Cytion, we offer a diverse collection of SNU (Seoul National University) cell lines harboring various KRAS mutations, providing researchers with valuable tools to study KRAS-driven oncogenesis and develop targeted therapies.

SNU Cell Lines Represent Diverse KRAS Mutation Profiles Found in Human Cancers

At Cytion, we've curated a comprehensive collection of SNU cell lines that showcase the heterogeneity of KRAS mutations observed across different cancer types. These cell lines, derived from patient tumors at Seoul National University, capture the genetic diversity that makes KRAS-driven cancers both challenging and fascinating research targets. Our SNU-C2B colorectal cancer line harbors the common G12D mutation, while our SNU-601 gastric cancer model features the G13D variant that alters downstream signaling in unique ways. This diversity enables researchers to investigate how specific KRAS mutations influence tumor biology, drug response, and potential therapeutic vulnerabilities across different tissue contexts.

Our Collection Includes Models for Colorectal, Gastric, and Lung Adenocarcinomas

Cytion's SNU cell line portfolio spans multiple cancer types, providing researchers with tissue-specific models to study KRAS-driven oncogenesis across different contexts. Our colorectal cancer models, including the SNU-C4 line with its G12V mutation, replicate the molecular features frequently observed in clinical KRAS-mutant CRC cases. For gastric cancer research, the SNU-216 and SNU-668 lines offer insights into how KRAS alterations influence gastric tumor progression and therapy resistance. Our lung adenocarcinoma models, such as the SNU-1330 line, capture the unique biology of KRAS mutations in lung cancer, which accounts for approximately 30% of cases in this tissue type. This tissue diversity enables comparative studies across cancer types, illuminating both common and context-specific mechanisms of KRAS-mediated transformation.

KRAS G12D, G12V, and G13D Mutations Are Well-Represented Across Our SNU Portfolio

Cytion's SNU collection provides comprehensive coverage of the most clinically relevant KRAS mutation variants. The G12D mutation, which substitutes glycine with aspartic acid at position 12, is featured in our SNU-175 and SNU-407 colorectal lines, representing one of the most common KRAS alterations in pancreatic and colorectal cancers. The G12V variant, where valine replaces glycine, is present in our SNU-C2A model, known for its aggressive phenotype and distinct signaling properties. For G13D mutations, which affect codon 13 and exhibit different biochemical properties than codon 12 alterations, our SNU-1033 line serves as an excellent research tool. Each mutation variant activates different downstream pathways with varying intensities, making these diverse models essential for developing mutation-specific therapeutic approaches.

These Cell Lines Enable Research on Mutation-Specific Oncogenic Pathways

At Cytion, we recognize that different KRAS mutations drive distinct signaling cascades and downstream effects. Our SNU cell lines provide researchers with valuable tools to dissect these mutation-specific pathways with precision. The SNU-61 line enables investigation of how G12D mutations preferentially activate the PI3K/AKT pathway, while our SNU-C1 model helps researchers explore G12V-mediated RAF/MEK/ERK signaling alterations. For studying the unique properties of G13D mutations, which show differential GAP sensitivity compared to codon 12 mutations, our SNU-503 line provides an ideal system. These cell models support pathway-focused drug discovery efforts, helping identify mutation-tailored therapeutic approaches that address the specific vulnerabilities of different KRAS-mutant tumors.

Cytion Provides Fully Characterized Models with Detailed Genetic Profiling Data

Quality and characterization are paramount in cancer cell model research, which is why all SNU cell lines in our KRAS-mutant collection undergo comprehensive genetic profiling. Each SNU cell line is supplied with detailed molecular characterization data, including complete mutation profiles, copy number variations, and gene expression patterns. Our SNU-C5 colorectal model comes with validated KRAS G12D mutation status and information on co-occurring genomic alterations that might influence research outcomes. For researchers investigating KRAS G12V variants, our SNU-719 line includes curated data on downstream pathway activation status, enabling more precise experimental design. This detailed characterization ensures researchers can select the most appropriate models for their specific research questions and interpret results within the full genetic context of each cell line.